China SXT Pharmaceuticals
SXTC
6 hedge funds and large institutions have $57K invested in China SXT Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
200% more funds holding
Funds holding: 2 → 6 (+4)
77% more capital invested
Capital invested by funds: $32.3K → $57K (+$24.8K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$29.6K |
| 2 |
HF
HRT Financial
New York
|
+$9.88K |
| 3 |
LFAS
Level Four Advisory Services
Dallas,
Texas
|
+$4.94K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$4.94K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.94K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$2.45K |
| 2 |
Renaissance Technologies
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $23.5K | +$29.6K | +6 | New |
|
2
Acadian Asset Management
Boston,
Massachusetts
| $12K | – | – | – |
|
|
TSS
3
Two Sigma Securities
New York
| $6.15K | +$4.94K | +1 | +100% |
|
|
LFAS
4
Level Four Advisory Services
Dallas,
Texas
| $5.26K | +$4.94K | +1 | New |
|
|
HF
5
HRT Financial
New York
| $5K | +$9.88K | +2 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $3.67K | +$4.94K | +1 | New |
|
|
BBA
7
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| $1.42K | – | – | – |
|
8
Qube Research & Technologies (QRT)
London,
United Kingdom
| $6 | – | – | – |
|
|
CAN
9
Cetera Advisor Networks
El Segundo,
California
| – | -$2.45K | – | – |
|
|
10
Renaissance Technologies
New York
| – | -$2K | – | – |
|
SXTC Hedge Fund Activity: Q3 2023 in Review
6 of the 6,303 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q3 2023, worth a combined $57K — up 77% from $32.3K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SXTC positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $29.6K. The largest seller was Cetera Advisor Networks, cutting an estimated $2.45K.
- 6 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q3 2023, up from 2 in Q2 2023.
- Funds reported $57K of China SXT Pharmaceuticals stock for Q3 2023, up 77% quarter-over-quarter.
- 4 funds opened new China SXT Pharmaceuticals positions in Q3 2023 and 0 closed out, a net change of +4 holders.
- The largest China SXT Pharmaceuticals buyer in Q3 2023 was Citadel Advisors, an estimated $29.6K added.
- The largest China SXT Pharmaceuticals seller in Q3 2023 was Cetera Advisor Networks, an estimated $2.45K sold.
Based on aggregated 13F filings for Q3 2023.